Revolution Medicines, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Revolution Medicines, Inc. (RVMD), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are RVMD insiders buying or selling?
In the last 12 months, Revolution Medicines, Inc. insiders reported 0 open-market purchases ($0) and 56 sales ($156.1M) — net selling of $156.1M. Since February 2020, Trabud has recorded 249 Form 4 filings for RVMD: 11 buys ($134.5M) and 238 sells ($445.4M).
Source: SEC EDGAR Form 4
What stands out
- No Revolution Medicines, Inc. insider made an open-market purchase in the last 12 months; the 56 reported open-market sales totaled $156.1M.
Key Statistics (February 2020 – Oct 1, 2026)
Total Form 4 filings
249
SEC EDGAR
Insider filers
20
Insider buys (11)
$134.5M
Insider sells (238)
$445.4M
Insider sentiment
Net sellingNet insider flow of $310.9M in net selling since February 2020, and $156.1M in net selling over the last 12 months.
Recent RVMD insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Alan B. Sandler | Chief Development Officer | Sale | 6.3K | $202.14 | $1.3M | SEC ↗ |
| Sep 29, 2026 | Jeff Cislini | SVP & General Counsel | Sale | 765 | $207.32 | $158.6K | SEC ↗ |
| Sep 28, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 3.7K | $200.45 | $743.3K | SEC ↗ |
| Sep 24, 2026 | Elizabeth M Anderson | Director | Sale | 10.1K | $193.04 | $2.0M | SEC ↗ |
| Sep 22, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 1.8K | $196.94 | $347.4K | SEC ↗ |
| Sep 18, 2026 | Alan B. Sandler | Chief Development Officer | Sale | 341 | $199.24 | $67.9K | SEC ↗ |
| Sep 18, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 1.8K | $199.24 | $353.4K | SEC ↗ |
| Sep 18, 2026 | Stephen Michael Kelsey | Senior Advisor to the Chief Executive Officer | Sale | 5.6K | $199.24 | $1.1M | SEC ↗ |
| Sep 18, 2026 | Margaret A Horn | Chief Operating Officer | Sale | 5.0K | $199.24 | $989.6K | SEC ↗ |
| Sep 18, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 14.0K | $199.24 | $2.8M | SEC ↗ |
| Sep 18, 2026 | Jeff Cislini | SVP & General Counsel | Sale | 3.4K | $199.24 | $670.6K | SEC ↗ |
| Sep 18, 2026 | Jack Anders | Chief Financial Officer | Sale | 4.1K | $199.24 | $807.5K | SEC ↗ |
| Sep 15, 2026 | Stephen Michael Kelsey | Senior Advisor to the Chief Executive Officer | Sale | 92.5K | $202.36 | $18.7M | SEC ↗ |
| Sep 14, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 15.4K | $204.16 | $3.2M | SEC ↗ |
| Sep 10, 2026 | Lorence H. Kim | Director | Sale | 17.1K | $209.82 | $3.6M | SEC ↗ |
| Sep 2, 2026 | Lorence H. Kim | Director | Sale | 56.0K | $203.24 | $11.4M | SEC ↗ |
| Aug 25, 2026 | Jeff Cislini | General Counsel | Sale | 56.9K | $209.24 | $11.9M | SEC ↗ |
| Aug 25, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 86.0K | $209.20 | $18.0M | SEC ↗ |
| Jul 1, 2026 | Sushil Patel | Director | Sale | 5.6K | $187.99 | $1.0M | SEC ↗ |
| Jun 26, 2026 | Jack Anders | Chief Financial Officer | Sale | 20.0K | $168.33 | $3.4M | SEC ↗ |
| Jun 18, 2026 | Anthony Mancini | Chief Global Commercialization Officer | Sale | 4.6K | $156.12 | $720.5K | SEC ↗ |
| Jun 18, 2026 | Mark A Goldsmith | President and Chief Executive Officer | Sale | 10.0K | $156.12 | $1.6M | SEC ↗ |
| Jun 18, 2026 | Jeff Cislini | General Counsel | Sale | 2.2K | $156.12 | $336.7K | SEC ↗ |
| Jun 18, 2026 | Jack Anders | Chief Financial Officer | Sale | 2.7K | $156.12 | $425.0K | SEC ↗ |
| Jun 18, 2026 | Stephen Michael Kelsey | President, Research and Development | Sale | 4.2K | $156.12 | $651.8K | SEC ↗ |
Showing the 25 most recent of 249 Form 4 filings for Revolution Medicines, Inc..
Most active RVMD insiders
- Mark A Goldsmith44 filings
- Stephen Michael Kelsey43 filings
- Margaret A Horn35 filings
- Jeff Cislini34 filings
- Jack Anders31 filings
Ask anything about RVMD insider activity
Use Trabud's AI agent to query Revolution Medicines, Inc.'s Form 4 history in plain English — "Show me RVMD CEO purchases this year" or compare it against any other ticker.
Open the AI agentRVMD insider trading FAQ
Are Revolution Medicines, Inc. insiders buying or selling?
In the last 12 months, Revolution Medicines, Inc. insiders reported 0 open-market purchases ($0) and 56 sales ($156.1M) — net selling of $156.1M. Since February 2020, Trabud has recorded 249 Form 4 filings for RVMD: 11 buys ($134.5M) and 238 sells ($445.4M). Over the full record that is net selling of $310.9M.
How many insiders trade RVMD stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Revolution Medicines, Inc.. The most recent filing was accepted on Oct 1, 2026.
Where does Trabud get RVMD insider trading data?
All RVMD insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.